NT$ 49.8
Key Takeaways
Risk factor
Poor trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Solid dividends
Data is available to registered users only
Data is available to registered users only
About
SciVision Biotech Inc. develops and manufactures medical-grade hyaluronic acid products in Taiwan. The company offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. It also involved in international trade; wholesale of medical equipment and cosmetics; and provides management advisory services. SciVision Biotech Inc. was founded in 1990 and is based in Kaohsiung, Taiwan.
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD.
Data is available to registered users only